AVR
Anteris Technologies Global Corp.
Healthcare — Medical Instruments & Supplies
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Price History
Fundamentals
| Market Cap | $763.16M |
| P/E Ratio (TTM) | - |
| Forward P/E | -8.00 |
| EPS (TTM) | $-2.22 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -11.20% |
| ROE | -59.21% |
| Debt/Equity | 1.34 |
| Recommendation | None |
| Analyst Target | $15.33 |
| Analysts | 3 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 25.0 |
| Beta | 0.73 |
| SMA 20 | $8.75 |
| SMA 40 | $9.22 |
| 52-Week High | $11.06 |
| 52-Week Low | $2.99 |
| 50-Day Avg | $9.17 |
| 200-Day Avg | $6.35 |
| Avg Volume | $1.25M |
| Volume | $1.03M |
Performance Analysis
NEUTRALAVR presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report